Flu

New data show mRNA-1010 diversifies B-cell responses well beyond what conventional hemagglutination-inhibition testing can capture.

Explore emerging flu antivirals, from season-long CD388 prevention to single-dose therapies, designed to beat current treatment limits.

A preclinical study demonstrates protective immunity against flu, COVID-19, and RSV without immune interference.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

The Moderna mRNA influenza vaccine won the FDA panel vote, but ACIP turmoil and a legal fight could threaten its fall 2026 rollout.

FDA approval of the first generic version of baloxavir marboxil brings an affordable single-dose flu treatment, boosting access for the 2026-27 influenza season.

What began as a modest survey has grown into one of the most trusted barometers of frontline pharmaceutical expertise in the country.

Educate patients to help avoid duplicate acetaminophen intake and prevent interactions, and know when to consult their physician.

The influenza vaccine halves the risk of heart attack and stroke after infection, offering cardiovascular protection even when breakthrough influenza occurs.

Data from a new 20-year analysis reveal persistent inequities in influenza vaccination among a high-risk cardiovascular population.

Dual-target flu immunity to HA and NA halves airborne spread in ferrets without escape mutations, reshaping next-generation vaccines and pharmacist counseling.

A single intranasal formulation demonstrated protection against SARS-CoV-2, bacterial pneumonia, and allergens for up to 3 months in preclinical models.

Thrifty White’s experiences provide practical lessons from designing, training, and standardizing a full-system model.

Pharmacists boost late-season flu, COVID-19, and RSV vaccination with coadministration guidance, fatigue-fighting messaging, and community access strategies.

The FDA accepts Moderna’s mRNA flu vaccine filing, targeting adults 50 years and older, with an accelerated path for older adults and a 2026 decision deadline.

The FDA declines to review Moderna’s mRNA flu vaccine filing over comparator choice, despite positive phase 3 results.

Various OTC analgesic and anesthetic products can be effective in providing prompt, temporary relief from discomfort.

Pharmacists enhance community health by offering test-and-treat services for COVID-19, influenza, strep, and RSV, improving access to care.

According to the news release, the manufacturers have 30 days to respond.

Discover how AI-engineered nasal antiviral platforms revolutionize flu prevention, enhancing mucosal immunity and offering new treatment possibilities.

Pharmacists can educate patients about FluMist for at-home administration and opioid labeling changes.

Researchers explore how immune history and innovative vaccine technologies enhance protection against flu, highlighting pharmacists' vital role in patient education.

New research reveals significant nonrespiratory complications in hospitalized children with influenza, highlighting the need for improved clinical awareness and antiviral treatment.

Counsel patients about effective remedies for pediatric colds, sore throats, and safe OTC options for adults with hypertension to alleviate symptoms.

Influenza significantly impacts agricultural workers in the Americas, highlighting urgent vaccination needs for public health and food security.